Navigation Links
Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
Date:3/17/2008

for the treatment of breakthrough pain in cancer and non-cancer patients. In December 2007, Alexza entered into an agreement with Endo Pharmaceuticals to jointly develop AZ-003. Endo is responsible for regulatory, pre-clinical and clinical development, and for commercializing the product in North America. Alexza is responsible for the development of the Staccato Electric Multiple Dose device and has the exclusive right to manufacture the product for clinical development and commercial supply.

-- AZ-007 (Staccato zaleplon) is being developed for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep. Alexza filed an Investigational New Drug application in December 2007. In March 2008, the Company completed enrollment in a Phase 1 clinical trial that enrolled 40 healthy volunteers at a single site. The purpose of this trial was to assess the safety, tolerability and pharmacokinetic parameters of a single dose of AZ-007. Using a double-blind, randomized trial design, four doses of AZ-007 (ranging from 0.5 to 4 mg) were compared to placebo. The Company expects to report initial results of this trial in the Q2 2008.

Financial Results -- Three and Twelve Months Ended December 31, 2007 and 2006

The net loss for the years ended December 31, 2007 and 2006, as reported in accordance with accounting principles generally accepted in the United States (GAAP), was $45.1 million and $41.8 million, respectively. GAAP R&D expenses were $13.7 million in the fourth quarter of 2007 and $45.6 million for the year ended December 31, 2007, as compared to $10.5 million and $36.5 million in the comparable periods in 2006. GAAP operating expenses were $17.4 million in the fourth quarter of 2007 and $60.5 million for the year ended December 31, 2007, as compared to $13.9 million and $46.5 million for the comparable periods in 2006. The increases resulted from
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis , ... laser tattoo removal experience with the advanced Astanza Duality laser and ... quality cosmetic services with cutting edge medical technology and offering expert ... has seen a dramatic increase in the presence of ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... PITTSBURGH, April 13, 2012 Mylan Inc. (Nasdaq: ... Pharmaceuticals Inc. has received final approval from the U.S. ... Drug Application (ANDA) for Fluvastatin Capsules USP, 20 mg ... Lescol ® Capsules. This product is indicated for ...
... Holdings, Inc. (NYSE: ZMH ; SIX: ZMH), a ... participating in the Bank of America Merrill Lynch 2012 Health ... Nevada, on May 16, 2012, at 10:00 a.m. Pacific Time. ... be accessed via Zimmer,s Investor Relations website at http://investor.zimmer.com ...
Cached Medicine Technology:Mylan Launches First Generic Version of LescolĀ® Capsules 2Zimmer Holdings to Present at the Bank of America Merrill Lynch 2012 Health Care Conference 2
(Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease is ... may be mistaken for foreign invaders and killed by ... autoimmune diseases like type I diabetes, celiac disease, and ... published April 16, 2014, in Nature Communications . ... in Parkinson,s disease; but if true, it could lead ...
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on conservation ... today examining the current state of knowledge of the ... improved global surveillance strategies to combat the emergence of ... in West Africa that has claimed the lives of ... According to the World Health Organization (WHO), the ...
(Date:4/17/2014)... Population Council scientists and their partners have found that ... prevent the transmission of multiple sexually transmitted infections (STIs) ... herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV). ... the gel is effective against multiple strains of HIV, ... against all three viruses of at least eight hours ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... Noted sand sculpture artist Sudarsan Patnaik used the sands of ... "Mother and Child" // . ,'Mother and Child' ... the Tourism Secretary A. Anbarasu. He unveiled the sculpture ... this year's Pulse Polio campaign that ends on Sunday. ...
... by other professionals including Bollywood stars in a peace ... increase for OBCs in higher educational institutions. ,"We ... and march towards Azad Maidan," Ashish Tiwari, convener of ... march will also demand that a judicial probe be ...
... the hilly and interior areas of Tripura's Dhalai district in ... ,Two helicopters were pressed into service for emergency landing ... ,Health Minister Tapan Chakraborty told reporters that he had directed ... medicines to the region. The state government was was making ...
... Electrosurgery employed in the removal of tonsils and adenoids ... of the cochlear implant device//, a new study has ... pave way for a safe, maximal pain-free and effective ... ,Cochlear implant (CI) recipients have been discouraged ...
... 'absolutely cruel' making wonder kid Budhia Singh run 65 kms to ... We are doing a diservice to that child,' Murthy told reporters ... athlete P T Usha who called the exercise 'wrong.' 'We should ... win the world marathon at the age of 16, or 17 ...
... device that can determine the gentleness of a surgeon while ... American doctor and colleague//. ,The invention of Dr ... in Chicago, and Dr Joseph Talarico, a surgical resident at ... stage of development. While the original idea is Maker's, Talarico ...
Cached Medicine News:Health News:Electrosurgery Ensures Integrity Of Cochlear Implant Following Adenoids Removal 2Health News:Electrosurgery Ensures Integrity Of Cochlear Implant Following Adenoids Removal 3
... Multiple blood chemistry testing. One-step testing. Average ... thirty day. Storage of up to 250 ... Automatic shut-off in two minutes from non-use ... Chip (included with each strip package). Results ...
SAS Strep A Test is a rapid visual test for the presumptive qualitative detection of Group A Streptococcal antigen from throat swab specimens. Group A streptococcus is the principal cause of respirat...
... ACON Strep A Twist Rapid Test Device (Throat ... format, utilizing a patented design to provide convenience ... a built-in swab chamber, eliminating the need for ... This test exhibits a 93% accuracy compared to ...
... System offers unparalleld speed, providing accurate, ... requiring only 10 ul of blood. ... more comprehensive patient care by spending ... CoaguChek S System is easy-to-use, accurate, ...
Medicine Products: